FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Italy Fines Apple €98.6 Million Over App Store Dominance 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19th Annual BIO CEO & Investor Conference in New York at 5:30 pm eastern time on Monday, February 13, 2017.
A live webcast of the presentation will be available on the company’s website at www.mateon.com in “Events & Presentations” under the “Investors & News” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACTS Investors: [email protected] 650-635-7000 Media: JPA Health Communications Nic DiBella [email protected] 617-945-5183
